Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

NBIX stock hub

Neurocrine Biosciences, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NBIXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

15.3B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

NBIX

In the news

Latest news · NBIX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E13.6

P25 12.3P50 18.4P75 33.1

Trailing P/E23.4

P25 14.9P50 23.2P75 38.5

ROE22.5

P25 -105.6P50 -46.5P75 -3.1

ROIC23.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NBIX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

268

Groups with data

Currency

USD

Showing 268 of 268 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000914475
Company name	Neurocrine Biosciences, Inc.
Country	United States
Country code	US
Cusip	64125C109
Employees	2,000
Employees Change	200%
Employees Change Percent	11.11
Enterprise value	$14.5B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	1996-05-23
Isin	US64125C1099
Last refreshed	2026-05-10
Market cap	$15.3B
Market cap category	Large-Cap
Price	$152
Price currency	USD
Rev Per Employee	1,551,200x
Sector	Healthcare
Sic	2836
Symbol	NBIX
Website	https://www.neurocrine.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	4.37%
EV Earnings	21.62x
EV Sales Forward	3.88x
EV/EBIT	18.1x
EV/EBITDA	17.45x
EV/FCF	17.39x
EV/Sales	4.66x
FCF yield	5.43%
Forward P/E	13.62x
P/B ratio	4.5x
P/E ratio	23.41x
P/S ratio	4.93x
PE Ratio10 Y	154.83x
PE Ratio3 Y	38.65x
PE Ratio5 Y	94.5x
PEG ratio	0.32x
PS Forward	4.11x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	25.75%
EBITDA Margin	26.71%
FCF margin	26.8%
Gross margin	64.37%
Gross Profit	$2B
Gross Profit Growth	29.51%
Gross Profit Growth Q	68.05%
Gross Profit Growth3 Y	23.11%
Gross Profit Growth5 Y	21.81%
Net Income	$668.6M
Net Income Growth	118.64%
Net Income Growth Q	2,405.06%
Net Income Growth Quarters	4%
Net Income Growth Years	4%
Net Income Growth3 Y	118.61%
Net Income Growth5 Y	10.71%
Pretax Margin	30.22%
Profit Margin	21.55%
Profit Per Employee	$334,300
Profitable Years	8
ROA	11.62
Roa5y	8.57
ROCE	19.6
ROE	22.5
Roe5y	12.08
ROIC	23.74
Roic5y	20.75

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	13.51%
Cagr15y	22.44%
Cagr1y	25.21%
Cagr20y	5.3%
Cagr3y	16.05%
Cagr5y	10.83%
EPS Growth	119.9
EPS Growth Q	2,310.5
EPS Growth Quarters	4
EPS Growth Years	4
EPS Growth3 Y	115.8
EPS Growth5 Y	9.71
FCF Growth	68.9%
FCF Growth Q	152.68%
FCF Growth3 Y	51.88%
FCF Growth5 Y	25.58%
OCF Growth	62.99%
OCF Growth Q	125%
OCF Growth3 Y	50.24%
OCF Growth5 Y	25.24%
Revenue Growth	28.59x
Revenue Growth Q	42.25x
Revenue Growth Quarters	19x
Revenue Growth Years	9x
Revenue Growth3 Y	24.74x
Revenue Growth5 Y	24.3x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.72
Assets	$4.9B
Cash	$1.3B
Current Assets	$2.4B
Current Liabilities	$831.7M
Debt	$463.5M
Debt EBITDA	$0.52
Debt Equity	$0.14
Debt FCF	$0.56
Equity	$3.4B
Liabilities	$1.5B
Long Term Assets	$2.5B
Long Term Liabilities	$667.1M
Net Cash	$852.7M
Net Cash By Market Cap	$5.57
Net Cash Growth	89.32%
Net Debt EBITDA	$-1.03
Net Debt Equity	$-0.25
Net Debt FCF	$-1.03
Tangible Book Value	$3.4B
Tangible Book Value Per Share	$33.87
WACC	5.92

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.93
Inventory Turnover	17.89
Net Working Capital	$345.5M
Quick ratio	2.51
Working Capital	$1.6B
Working Capital Turnover	$2.28

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.68%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	255.14%
1Y total return	25.2%
200-day SMA	137.6
3Y total return	56.31%
50-day SMA	131.6
50-day SMA vs 200-day SMA	50under200
5Y total return	67.23%
All Time High	160.2
All Time High Change	-4.95%
All Time High Date	2025-12-08
All Time Low	1.94
All Time Low Change	7,747.94%
All Time Low Date	2009-11-30
ATR	4.43
Beta	0.34
Beta1y	0.68
Beta2y	0.67
Ch YTD	7.35
High	154.7
High52	160.2
High52 Date	2025-12-08
High52ch	-4.95%
Low	149.5
Low52	115.7
Low52 Date	2025-05-09
Low52ch	31.64%
Ma50ch	15.68%
Premarket Change Percent	-1.56
Premarket Price	$147
Price vs 200-day SMA	10.65%
RSI	78.42
RSI Monthly	60.81
RSI Weekly	62.71
Sharpe ratio	0.76x
Sortino ratio	1.27
Total Return	0.68%
Tr YTD	7.35
Tr15y	1,982.76%
Tr1m	16.31%
Tr1w	15.53%
Tr3m	7.83%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	21
Analyst Count Top	13
Analyst Price Target Top	$181
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$1.61
Earnings EPS Estimate Growth	130
Earnings Revenue Estimate	763,112,064x
Earnings Revenue Estimate Growth	33.27x
Operating Income	$798.8M
Operating Income Growth	54.99
Operating Income Growth Q	684.8
Operating Income Growth3 Y	42.58
Operating Income Growth5 Y	21.63
Operating margin	25.75
Price target	$184
Price Target Change	$21.01
Price Target Change Top	$18.58

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	99,259,897%
Float Percent	98.72%
Shares Insiders	1.21%
Shares Institutions	99.48%
Shares Out	100,549,983
Shares Qo Q	-0.29%
Shares Yo Y	-0.68%
Short Float	5.69%
Short Ratio	5.23
Short Shares	5.61

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$609M
Average Volume	1,258,680.5x
Bv Per Share	33.87
CAPEX	$-32.4M
Ch10y	255.1
Ch15y	1,982.8
Ch1m	16.31
Ch1w	15.53
Ch1y	25.2
Ch20y	181
Ch3m	7.83
Ch3y	56.31
Ch5y	67.23
Ch6m	-0.08
Change	1.78%
Change From Open	1.5
Close	149.6
Days Gap	0.27
Depreciation Amortization	29,800,000
Dollar Volume	215,429,487
Earnings Date	2026-05-05
Earnings Time	amc
EBIT	$798.8M
EBITDA	$828.6M
EPS	$6.5
F Score	6
FCF	$831.3M
FCF EV Yield	5.75x
FCF Per Share	$8.27
Financing CF	-6,500,000
Fiscal Year End	December
Founded	1,992
Graham Number	70.39533
Graham Upside	-53.76
Income Tax	$268.9M
Investing CF	-784,800,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-05
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-11
Lynch Fair Value	$69.64
Lynch Upside	-54.26
Ma150	137.9
Ma150ch	10.42%
Ma20	133.5
Ma20ch	14.05%
Net CF	72,400,000
Next Earnings Date	2026-07-29
Open	150
Optionable	Yes
P FCF Ratio	18.42
P OCF Ratio	17.72
Position In Range	52.12
Post Close	152.3
Postmarket Change Percent	-0.16
Postmarket Price	$152
Ppne	538,000,000
Pre Close	149.6
Price Date	2026-05-08
Price EBITDA	$18.48
Ptbv Ratio	4.49
Relative Volume	1.12x
Revenue	3,102,400,000x
SBC By Revenue	7.17x
Share Based Comp	222,300,000
Tax By Revenue	8.67x
Tax Rate	28.68%
Tr20y	180.96%
Tr6m	-0.08%
Us State	California
Volume	1,414,972
Z Score	6.99

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does NBIX pay a dividend?

Capital-return profile for this ticker.

Performance

NBIX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NBIX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+99.5%

Float: +98.7% of shares outstanding

Insider ownership

+1.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

NBIX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

78.4

Above 70: short-term overbought

Price vs 200-day MA

+10.7%

50/200-day relationship not available

Beta (5Y)

0.34

Less volatile than the market

Sharpe ratio

0.76

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NBIX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current NBIX stock rating?

Neurocrine Biosciences, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full NBIX analysis?

The full report lives at /stocks/NBIX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for NBIX?

The latest report frames NBIX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the NBIX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.